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CAENORHABDITIS ELEGANS AS A MODEL SYSTEM
The nematode Caenorhabditis elegans (C. elegans) is a 
multicellular organism that has become a popular model for 
biological and basic medical research. It has also been widely 
used as a model system to explore fundamental questions in 
multiple aspects of biology, including evolution, development, 
cell fate specification, stem cell regulation, tumorigenesis, and 
aging. The C. elegans has also been considered as an ideal 
model system for live animal high-throughput drug screen-
ing, as 1) their tissues are transparent at all developmental 
stages, 2) tissue-specific fluorescent transgenic markers to 
study physiological and cellular processes in vivo are well es-
tablished, 3) a large number of mutant strains are available in 
Caenorhabditis Genetics Center (CGC) [http://www.cbs.umn.
edu/research/resources/cgc], 4) whole genome sequenc-
ing has been completed, 5) they have a short lifespan (2 to 
3 weeks) and a strong genetic power, and 6) the aspects of 
mammalian diseases can be successfully modeled in the C. 
elegans (O'Reilly et al., 2014). 
The C. elegans life cycle includes embryogenesis (~12 h), 
four larval stages (L1-L4; total of ~3 days) and adulthood (~10 
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The nematode Caenorhabditis elegans (C. elegans) offers a unique opportunity for biological and basic medical researches due 
to its genetic tractability and well-defined developmental lineage. It also provides an exceptional model for genetic, molecular, 
and cellular analysis of human disease-related genes. Recently, C. elegans has been used as an ideal model for the identification 
and functional analysis of drugs (or small-molecules) in vivo. In this review, we describe conserved oncogenic signaling pathways 
(Wnt, Notch, and Ras) and their potential roles in the development of cancer stem cells. During C. elegans germline development, 
these signaling pathways regulate multiple cellular processes such as germline stem cell niche specification, germline stem cell 
maintenance, and germ cell fate specification. Therefore, the aberrant regulations of these signaling pathways can cause either 
loss of germline stem cells or overproliferation of a specific cell type, resulting in sterility. This sterility phenotype allows us to identi-
fy drugs that can modulate the oncogenic signaling pathways directly or indirectly through a high-throughput screening. Current in 
vivo or in vitro screening methods are largely focused on the specific core signaling components. However, this phenotype-based 
screening will identify drugs that possibly target upstream or downstream of core signaling pathways as well as exclude toxic ef-
fects. Although phenotype-based drug screening is ideal, the identification of drug targets is a major challenge. We here introduce 
a new technique, called Drug Affinity Responsive Target Stability (DARTS). This innovative method is able to identify the target of 
the identified drug. Importantly, signaling pathways and their regulators in C. elegans are highly conserved in most vertebrates, 
including humans. Therefore, C. elegans will provide a great opportunity to identify therapeutic drugs and their targets, as well as 
to understand mechanisms underlying the formation of cancer.
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days) (Kimble and Crittenden, 2005). C. elegans exists as ei-
ther hermaphrodites or males. Wild-type hermaphrodites can 
produce sperm during larval development (L3-L4) and then 
switch to oogenesis in adulthood (Fig. 1A, 1C). However, 
males make sperm continuously throughout their lifespan. In 
addition, the germline is organized in a simple linear fashion 
that progresses from germline stem cells at one end to matur-
ing gametes at the other (Fig. 1B, 1C). C. elegans germline 
development is tightly regulated by conserved external sig-
naling pathways, including Wnt, Notch and Ras, (Fig. 1B) as 
well as intrinsic regulators, including gene expression regula-
tors and cell cycle regulators (Kimble and Crittenden, 2007). 
Aberrant control of these signaling pathways can cause the 
loss of the somatic distal tip cells (DTCs, which function as the 
germline stem cell niche) and germline stem cells as well as 
extra DTC formation, uncontrolled germline proliferation, and 
abnormal germ cell fate specification that are all associated 
with sterility and germline tumors. Therefore, these features 
of C. elegans germline make it a very suitable organism for 
the phenotype-based high-throughput screening of drugs that 
target oncogenic signaling pathways and the identification of 
therapeutic targets.
ONCOGENIC PATHWAYS: WNT SIGNALING 
Overview of Wnt signaling pathway 
The Wnt signaling pathway is critical for many aspects of 
animal development, including stem cell self-renewal, differ-
entiation, cell fate specification, polarity, and cell migration 
(Katoh, 2008). There are three Wnt signaling pathways: ca-
nonical Wnt/β-catenin pathway, non-canonical Wnt/planar cell 
polarity (PCP) pathway, and non-canonical Wnt/calcium path-
way (James et al., 2008). All three Wnt signaling pathways 
are activated by the binding of Wnt ligand to Frizzled family 
receptor. In absence of its ligand, cytoplasmic β-catenin in-
teracts with APC (polyposis coli) and Axin scaffold proteins, 
and then is phosphorylated by CKIα kinase and GSK3β (Gly-
cogen Synthase Kinase 3β). The phosphorylated β-catenin is 
then ubiquitinated and degraded by the proteasome (Fig. 2A). 
Therefore, in the canonical pathway, CKIα, GSK3β, APC, and 
Axin act as negative regulators. Upon activation, the forma-
tion of APC/Axin/CKIα/GSK3β destruction complex is inhib-
ited, which stabilizes β-catenin and leads to its localization in 
the nucleus (Fig. 2B). In the nucleus, β-catenin interacts with 
TCF family transcription factors to activate the expression of 
target genes such as FGF20, DKK1, WISP1, MYC, and Cy-
clin D1 (He et al., 1998; Pennica et al., 1998; Tetsu and Mc-
Cormick, 1999; Chamorro et al., 2005) (Fig. 2B). Importantly, 
these target genes have been implicated in the development 
of multiple types of cancer, including colon, breast, ovarian, 
and thyroid.
Wnt signaling and cancer stem cells 
Over the past several years, increasing evidence has been 
found to be in support of the theory of cancer stem cells 
(sometimes called tumor stem cells or tumor-initiating cells). 
Cancer cells are heterogeneous, containing abundant prolifer-
ative cells (non-cancer stem cells) and rare cancer stem cells. 
Furthermore, it has been proven that cancer stem cells are 
similar to normal stem cells in many aspects and exist in multi-
ple cancers such as leukemia, breast cancer, and lung cancer 
(Visvader and Lindeman, 2012). Therefore, specific therapies 
targeted at cancer stem cells hold a tremendous promise to 
increase the efficiency and safety of cancer treatment. 
The canonical Wnt/β-catenin is critical for the regulation of 
embryonic stem cells, adult stem cells, and cancer stem cells 
(Nusse et al., 2008). In normal stem cells, the self-renewal 
and differentiation of stem cells are tightly regulated at least 
in part by Wnt/β-catenin signaling. For example, R-spondin 
growth factors interact with Leucine-rich repeat-containing G-
protein-coupled receptors (Lgr) (Chen et al., 2013; Wang et 
al., 2013). These R-spondin/Lgr complexes and Wnt ligands 
Fig. 1. C. elegans and conserved signaling pathways. (A) An adult 
wild-type (N2) hermaphrodite stained with DAPI (4',6-diamidino-
2-phenylindole). The hermaphrodite has two gonadal tubes. They 
produce both sperm and oocytes, and are therefore self-fertile (see 
embryos). (B) A dissected adult hermaphrodite germline stained 
with DAPI. In the distal end, somatic gonadal cell, called DTC (see 
dotted red circle), acts as a germline stem cell niche that is essen-
tial for germline stem cell maintenance. The DTC fate is specified 
at least in part by Wnt/β-catenin signaling in early larval stage (L1). 
In the distal mitotic region (see dotted yellow lines), GLP-1/Notch 
signaling maintains germline stem cell self-renewal and promotes 
mitotic cell cycle of progenitor cells. Once mitotic cells enter mei-
otic cell cycle, Ras-ERK MAPK signaling promotes meiotic germ 
cell progression (see dotted green lines), pachytene exit (see dot-
ted yellow lines), oocyte maturation (see dotted pink lines; circle, 
oocyte nuclei) and sperm (see dotted blue lines) fate specification. 
(C) Schematic of an adult C. elegans hermaphrodite gonad. So-
matic DTC is located at the distal end. Cells at the distal end of the 
germline, including germline stem cells, divide mitotically (yellow). 
As cells move proximally, they enter meiosis (green) and differenti-
ate into either sperm (blue) or oocytes (pink).
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directly interact with Frizzled receptors on target cells to acti-
vate downstream signaling (Birchmeier, 2011). This signaling 
and downstream activation have been found to be important 
for the self-renewal and differentiation of stem cells and can-
cer stem cells (Reya and Clevers, 2005; Holland et al., 2013). 
Notably, Wnt/β-catenin signaling is likely to control mammary 
gland stem cell maintenance at different stages of develop-
ment (Wend et al., 2010; Holland et al., 2013). Mammary 
gland stem cells can give rise to ductal, basal/myoepithelial 
and alveolar components (Holland et al., 2013). Therefore, 
aberrant activation of Wnt/β-catenin signaling contributes to 
the maintenance of cancer stem cells and results in mammary 
gland tumorigenesis. In addition, Wnt/β-catenin signaling has 
been implicated in the regulation of stem cells and cancer 
stem cells in the nervous system, hematopoietic system, skin, 
and intestine (Holland et al., 2013). Therefore, the inhibition of 
Wnt/β-catenin signaling might reduce the capacity of cancer 
stem cells, which could be of potential therapeutic benefit in 
treating multiple types of cancer.
C. elegans canonical Wnt/β-catenin signaling 
Conserved Wnt/β-catenin signaling pathways and core 
components in C. elegans somatic gonads are summarized 
in Fig. 2C, and well described in (Eisenmann, 2005). This 
Fig. 2. Wnt/β-catenin signaling pathways and a strategy for the phenotype-based drug identification using C. elegans mutants. (A) With-
out signaling (absence of ligand), negative regulators (CKIα, GSK3β, Axin, and APC) phosphorylate β-catenin, and then ubiquitinated and 
degraded by the proteasome. (B) With signaling (presence of ligand), stabilized β-catenin in cytoplasm is translocated into nucleus and 
activate the expression of target genes. (C) Genetic pathway for control DTC fate specification (see text for explanation). (D) Wild-type her-
maphrodite has two DTCs. lag-2::GFP reporter is strongly expressed in DTCs (see green). (E) Loss of Wnt/β-catenin signaling affects DTC 
fate specification. (F) Activation of Wnt/β-catenin signaling contributes to extra DTC formation. (G) Strategy for the phenotype-based identifi-
cation of drugs that either inhibit or activate Wnt/β-catenin signaling using C. elegans mutants. 
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review focuses chiefly on canonical Wnt/β-catenin signaling 
that specifies a germline stem cell niche (known as a DTC in 
C. elegans) fate specification in the C. elegans gonad (Fig. 
2D). The DTC functions as the germline stem cell niche, which 
is essential for germline stem cell maintenance (Kimble and 
Crittenden, 2007). During early larval development, the DTC 
arises initially from an asymmetric cell division of a somatic 
gonadal progenitor (SGP) cell (Fig. 2C). This division specifies 
one daughter DTC potential and another non-DTC potential 
(Kimble and Crittenden, 2007; Byrd et al., 2014). In hermaph-
rodites, the DTC potential divides asymmetrically once more 
to differentiate terminally to form the DTC. The DTC fate is 
specified by divergent Wnt/β-catenin signaling pathways (Fig. 
2C). The pathway regulating the asymmetric division of precur-
sor cells, Z1 and Z4, involves Frizzled receptors (LIN-17 and 
MOM-5), Dishevelled proteins (DSH-2 and MIG-5), β-catenin 
(SYS-1), and TCF transcription factor (POP-1) (Kimble and 
Crittenden, 2007; Byrd et al., 2014) (Fig. 2C). Aberrant regu-
lation of this pathway results in either the loss of DTC fate 
(Fig. 2E) or the generation of extra DTCs by symmetric divi-
sion (Fig. 2F). Importantly, POP-1/TCF and SYS-1/β-catenin 
directly activate the transcription of ceh-22 (Nkx2.5 homolog 
in mammals) in DTC potentials (Lam et al., 2006) (Fig. 2C). 
CEH-22/Nkx2.5 is necessary for DTC specification (Lam et al., 
2006). Therefore, Wnt/β-catenin signaling and its direct tar-
gets (e.g., CEH-22) play an essential role in DTC fate specifi-
cation in the C. elegans gonads (Fig. 2C-2F).
Phenotype-based drug screening for Wnt/β-catenin 
signaling mutants
In C. elegans, the DTC functions as a germline stem cell 
niche, and it employs GLP-1/Notch signaling to promote con-
tinued mitotic divisions. The DTC fate is regulated by Wnt/β-
catenin signaling and its direct target, CEH-22/Nkx2.5 (Lam 
et al., 2006; Kimble and Crittenden, 2007). Therefore, weak 
or no Wnt signaling results in DTC loss and consequently no 
germline stem cells, which cause either partially or completely 
sterile (Fig. 2E). To visualize DTCs, a molecular marker lag-
2::GFP reporter gene can be used. This GFP marker is ex-
pressed brightly in DTCs (Fig. 2D, see green) (Blelloch and 
Kimble, 1999). The lag-2 is one of C. elegans Notch ligands 
and expressed in the DTC (Henderson et al., 1994; Blelloch et 
al., 1999). Normally, wild-type hermaphrodites have two DTCs 
(Byrd and Kimble, 2009) (Fig. 2D). However, loss of POP-1, 
SYS-1 or CEH-22 eliminates DTC fate (Fig. 2E), and ecto-
pic SYS-1 or CEH-22 produces extra DTCs and generates 
new germline stem cell populations (Fig. 2F, Table 1) (Kimble 
and Crittenden, 2007; Byrd et al., 2014). Indeed, the ceh-22 
gene is a direct target of transcriptional activation by POP-1/
TCF and SYS-1/β-catenin (Fig. 2C) (Lam et al., 2006) and is 
expressed in the cells with DTC potential (Lam et al., 2006). 
Notably, about 40% of ceh-22 mutants are missing both DTCs 
and are completely sterile. 40% of them are missing one of 
two DTCs and are partially sterile, and 20% of them produce 
two DTCs and are fertile (Lam et al., 2006). Amazingly, ecto-
pic expression of ceh-22 gene produces extra DTCs (Fig. 2F, 
Table 1) (Lam et al., 2006). Therefore, ceh-22 (q632) loss-
of-function mutant is an attractive allele to identify drugs that 
can inhibit or activate the Wnt/β-catenin signaling pathway. If a 
drug inhibits Wnt/β-catenin directly or indirectly, it will enhance 
DTC loss and produce the sterile phenotype of ceh-22 mutants 
(Fig. 2G left). By contrast, if the drug activates Wnt/β-catenin 
signaling, it will retain the fertility of ceh-22 mutants and will 
result in two or more DTCs (Fig. 2G right). Furthermore, if 
the drug suppresses the inhibitor of Wnt/β-catenin signaling 
directly or indirectly, it can activate Wnt/β-catenin signaling 
and may retain the fertility of ceh-22 mutants. The DTC fate is 
also regulated at least in part by cell cycle regulators. Tilmann 
and Kimble have previously reported that Cyclin D is required 
for DTC fate specification (Tilmann and Kimble, 2005). More-
over, we also found that cell cycle regulators work together 
with Wnt/β-catenin signaling to specify DTC fate (Lee et al., 
2014). Therefore, it suggests a possibility that the identified 
drugs can target the cell cycle regulators and/or Wnt/β-catenin 
signaling. The specificity can be examined by chemical genet-
ics in Wnt/β-catenin mutants or cell cycle mutants. Therefore, 
Table 1. Summary of oncogenic signaling pathways and mutant phenotypes
Signaling pathway Mutants or transgenic lines Phenotypes Reference
Wnt/β-catenin signaling pop-1(q645) DTC loss (100%) and sterile (Siegfried and Kimble, 2002)
sys-1(q544) DTC loss (100%) and sterile (Kidd et al., 2005)
lin-17(n671) DTC loss (<10%) and partially sterile (Phillips et al., 2007)
ceh-22(q632) DTC loss (~40%) and partially sterile (Lam et al., 2006)
hs::sys-1 Extra DTCs and fertile (Kidd et al., 2005)
hs::ceh-22 Extra DTCs and fertile (Lam et al., 2006)
GLP-1/Notch signaling glp-1(q46) No GSCs (“Glp” phenotype) (Austin and Kimble, 1987)
glp-1(bn18)ts
glp-1(q224)ts
Fertile at 20oC 
“Glp” phenotype at 25oC
(Nadarajan et al., 2009)
(Maine and Kimble, 1989)
glp-1(ar202)ts Fertile at 20oC 
Germline tumors at 25oC
(Pepper et al., 2003a)
Ras-ERK MAPK signaling mpk-1(ga117) Pachytene arrest and sterile (Lackner and Kim, 1998)
mpk-1(ga111)ts Pachytene arrest and sterile at 25oC (Lackner and Kim, 1998)
let-60(n1046) Multi-layered small oocytes and 
Multivulva (Muv) phenotype
(Hajnal and Berset, 2002)
(Beitel et al., 1990)
puf-8(q725); lip-1(zh15) Mog sterile at 20oC 
Germline tumors at 25oC
(Morgan et al., 2010)
(Cha et al., 2012)
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diverse C. elegans mutants for Wnt/β-catenin signaling will 
provide a great opportunity to identify drugs that can potential-
ly treat Wnt/β-catenin signaling-associated human diseases 
such as colon cancer.
ONCOGENIC PATHWAYS: NOTCH SIGNALING 
Overview of Notch signaling  
In most multicellular organisms, the Notch signaling path-
way is a highly conserved signaling pathway that controls 
proliferation, differentiation, cell fate specification, and apop-
tosis (Artavanis-Tsakonas et al., 1999). Notch and most of 
its ligands (DSL: Delta/Serrate/LAG-2) are trans-membrane 
proteins. Notch ligands are expressed in the cells that are 
adjacent to the Notch expressing cells. In absence of Notch 
ligand, CSL (CBF1, Suppressor of Hairless, LAG-1) transcrip-
tion factors are associated with co-repressors (Fig. 3A). This 
complex inhibits the expression of Notch target genes (Fig. 
3A). Once the Notch interacts with a ligand, an ADAM-family 
metalloprotease cleaves the outside of Notch receptor (Fig. 
3B). After this cleavage, γ-secretase cleaves the remaining 
part of the Notch receptor inside the inner leaflet of the cell 
membrane (Fig. 3B). This releases the intracellular domain 
of the Notch (NICD), which then translocates to the nucleus 
(Fig. 3B). In the nucleus, the NICD forms a complex with CSL 
(CBF1, Suppressor of Hairless, LAG-1) transcription factors 
and mastermind-like protein (MAML-1) to activate the expres-
sion of target genes (Fig. 3B). Importantly, an aberrant Notch 
signaling pathway potentially contributes to cancer develop-
ment in several different ways (Allenspach et al., 2002) or to 
loss of the specific cell type (Liu et al., 2010). Therefore, the 
Notch signaling pathway represents a novel target for cancer 
therapeutic intervention and regenerative medicine. 
Notch signaling and cancer stem cells 
Aberrant activation of Notch signaling has been detected 
in a variety of human cancers including pancreatic cancer 
(Ristorcelli and Lombardo, 2010; Avila and Kissil, 2013), col-
on cancer (Miyamoto and Rosenberg, 2011), osteosarcoma 
(Hughes, 2009), glioblastoma (Lino et al., 2010), lung cancer 
(Galluzzo and Bocchetta, 2011), head and neck cancer (Sun 
et al., 2014), and breast cancer (Reedijk, 2012). Notably, ac-
tivation mutations of human Notch1 are reported in approxi-
mately 50% of T-ALL (acute lymphoblastic leukemia) cases 
(Ferrando, 2009). The role of Notch in stem cell regulations 
has been thoroughly studied in several model systems to 
date. Moreover, the role of the Notch signaling in the initiation 
and maintenance of cancer stem cells has recently become 
a subject of study in a number of diverse model organisms. 
For example, Notch signaling is upregulated in pancreatic 
cancer stem cells (Abel et al., 2014). Reduction of the Notch 
signaling by either genetic inhibition (e.g. Hes1 shRNA) or 
drug treatment (e.g., γ-secretase inhibitor) in pancreatic can-
cer decreased cancer stem cell population and tumorsphere 
formation (Abel et al., 2014). In addition, the inhibition of Notch 
signaling by treatment with GSI-18 (γ-secretase inhibitor) de-
pleted the stem cell-like subpopulation derived from medul-
loblastoma cell lines and abolished xenograft formation (Fan 
et al., 2006). By contrast, the activation of the Notch signaling 
pathway with DSL peptide stimulated tumorsphere formation 
and increased cancer stem cell population (Abel et al., 2014). 
Bao et al. also reported that Notch-1 activation induced cancer 
stem cell self-renewal capacity through epithelial-mesenchy-
mal transition (EMT) (Bao et al., 2011). Therefore, the Notch 
signaling pathway is important in maintaining cancer stem cell 
population, and targeting its pathway in cancer has promising 
therapeutic potential.  
C. elegans Notch signaling
The Notch signaling pathway and its core components in C. 
elegans are highly conserved. The C. elegans has two Notch 
receptors, GLP-1 and LIN-12, which mediate cell-cell inter-
action during development (Greenwald, 2005). Specifically, 
GLP-1/Notch signaling in the C. elegans germline is critical 
for germline stem cell maintenance and continued mitotic divi-
sion (Kimble and Crittenden, 2007). LIN-12/Notch signaling in 
the C. elegans somatic cells specifies vulva cell fate during 
early larval stages (Greenwald, 2005). When LAG-2 (GLP-1/
Notch ligand) is expressed in DTCs (Fig. 3C) (Henderson et 
al., 1994) and interacts with the GLP-1/Notch receptor, pro-
teolytic cleavage of the GLP-1/Notch receptor follows (Fig. 
3C). GLP-1/Notch intracellular domain (NICD) is then trans-
located from the membrane into the nucleus (Fig. 3C). In the 
nucleus, the NICD forms a tertiary complex with LAG-1/CSL 
DNA binding protein and LAG-3/SEL-8/Mastermind transcrip-
tion co-activator to activate the expression of target genes: 
fbf-2 (PUF RNA-binding protein) (Lamont et al., 2004) and lip-
1 (MAPK phosphatase) (Berset et al., 2001; Lee et al., 2006), 
lst-1 (Nanos-like zinc finger domain-containing protein) (Yoo 
et al., 2004; Kershner et al., 2014), and sygl-1 (Novel protein) 
(Kershner et al., 2014) (Fig. 3C). Importantly, FBF-2, and LIP-
1 inhibit meiosis-promoting regulators (e.g., GLD-1, GLD-2, 
GLD-3, and MPK-1) in the C. elegans germline (Yoo et al., 
2004; Lee et al., 2006; Kimble and Crittenden, 2007; Lee et 
al., 2007a). Therefore, loss of GLP-1/Notch signaling in germ-
line causes a severe proliferation defect during early meiotic 
entry, resulting in no germline stem cell maintenance and ste-
rility (Fig. 3D) (Austin and Kimble, 1987), while constitutive 
activation of this signaling promotes proliferation of germline 
stem cells and their progenitor cells as well as inhibits entry 
into meiosis, resulting in germline tumors and sterility (Fig. 3E) 
(Berry et al., 1997). Therefore, the aberrant regulation of GLP-
1/Notch signaling can cause either loss of germline stem cells 
or overproliferation of a specific cell type, resulting in sterility.
       
Phenotype-based drug discovery for Notch signaling  
using glp-1 mutants
The C. elegans has multiple Notch mutants, including 
glp-1(q46) or glp-1(q175) null mutants, glp-1(bn18 or q224) 
temperature-sensitive (ts), loss-of-function (lf) mutants, and 
glp-1(ar202) temperature sensitive (ts), gain-of-function (gf) 
mutant (Table 1). In C. elegans germline, GLP-1/Notch sig-
naling is essential for germline stem cell maintenance and 
mitotic germ cell proliferation (Kimble and Crittenden, 2007). 
For example, at 20oC or lower, temperature sensitive, loss-
of-function mutants for glp-1, “glp-1(bn18) and glp-1(q224)” 
produce sperm and oocytes and are therefore fertile (Fig. 3D 
and 3E left). Conversely, at 25oC, they have a severe prolifera-
tion defect and early meiotic entry (Fig. 3D right). However, 
a temperature sensitive, gain-of-function mutant for glp-1, 
“glp-1(ar202)” with constitutively active GLP-1/Notch signal-
ing promotes proliferation of germline stem cells and inhibits 
entry into meiosis, resulting in germline tumors at 25oC (Fig. 
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3E right) (Pepper et al., 2003b). Notably, this germline tumor 
phenotype is rescued by the depletion of GLP-1/Notch sig-
naling component genes, including LAG-3/SEL-8/mastermind 
(Petcherski and Kimble, 2000). Therefore, glp-1(lf) or glp-1(gf) 
mutants are useful animals for the identification of drugs that 
may target GLP-1/Notch signaling positively or negatively (Fig. 
3F). The specificity can be tested by measuring the expression 
of direct GLP-1/Notch signaling target genes (e.g., fbf-2, lip-1, 
Fig. 3. Notch signaling pathways and a strategy for the phenotype-based drug identification using C. elegans mutants. (A) Without sig-
naling, negative regulators inhibit the expression of Notch target genes. (B) With signaling, cleaved NICD transports from membrane to 
nucleus. In nucleus, NICD form a ternary complex with CSL and co-activator, mastermine-like protein, to activate the expression of target 
genes. (C) C. elegans GLP-1/Notch signaling pathways. The DTC expresses GLP-1/Notch ligands (e.g., LAG-2) and employs GLP-1/Notch 
signaling to promote continued mitotic divisions. (D) In mutants lacking any of the core elements of the GLP-1/Notch signaling pathways (e.g., 
glp-1 loss-of-function mutant), germ cells leave the mitotic cell cycle, enter meiosis, and undergo gametogenesis, resulting in no germline 
stem cells and sterility. Most temperature-sensitive glp-1(bn18) loss-of-function mutants are fertile at 20°C, but they are sterile at 25°C. (E) 
Constitutively active GLP-1/Notch signaling develop germline tumors. Most temperature-sensitive glp-1(ar202) gain-of-function mutants are 
fertile at 20°C, but they are sterile due to germline tumors at 25°C. (F) Strategy for the phenotype-based identification of drugs that either 
inhibit or activate Notch signaling using C. elegans mutants. 
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lst-1, or sygl-1) (Lamont et al., 2004; Lee et al., 2006; Kersh-
ner et al., 2014) or by analyzing the effect of drugs on GLP-1/
Notch-unrelated synthetic mutants with germline tumors (e.g., 
gld-3, nos-3) (Eckmann et al., 2002). Together, C. elegans 
GLP-1/Notch signaling pathways and their core components 
are highly conserved in vertebrates, including humans. There-
fore, the identification and characterization of such drugs will 
provide a tremendous promise for cancer therapy.
ONCOGENIC PATHWAYS: RAS SIGNALING 
Overview of Ras signaling pathway
Ras-ERK MAP (Mitogen Activated Protein) kinase (MAPK) 
signaling pathways are highly conserved in all eukaryotes 
and are involved in numerous cellular responses including 
proliferation, differentiation, cell fate specification, cellular ho-
meostasis, and survival (Fig. 4A) (Marshall, 1995; Whelan et 
al., 2012). Extracellular stimuli such as growth hormone ac-
tivate Ras-ERK MAPK signaling through a MAPK signaling 
cascade. In short, extracellular ligands bind to the epidermal 
growth factor receptor (EGFR) and activate tyrosine kinase 
activity of the cytoplasmic domain of the EGFR (Fig. 4A).  The 
EGFR-binding adaptor, Grb2, binds to the phosphotyrosine 
residues of the activated receptor (Schulze et al., 2005) and 
to the guanine nucleotide exchange factor, SOS, through two 
SH3 domains of GRB2. This Grb2/SOS complex when docked 
to phosphorylated EGFR is activated, which then promotes 
the activation of Ras proteins (Fig. 4A). Activated Ras phos-
phorylates and activates RAF kinase, activated RAF phos-
phorylates and activates MEK, and activated MEK phosphory-
lates and activates ERK MAPK (Fig. 4A). Finally, activated 
ERK MAPK regulates its downstream targets in the positive 
or negative manners by phosphorylation (Fig. 4A). The down-
stream targets include transcription regulators (e.g., GATA-1) 
(Towatari et al., 2004), translational regulators (e.g., p90 ribo-
somal S6 kinases: RSK1, 2, 3) (Zhao et al., 1996), cell cycle 
regulators (e.g., Cyclin D1) (Okabe et al., 2006), and apopto-
sis regulators (e.g., BCL-2) (Tamura et al., 2004). Therefore, 
aberrant activation of Ras-ERK MAPK signaling contributes 
to abnormal gene expression, cell cycle progression, prolif-
eration, and survival. Notably, a constitutively active Ras-ERK 
MAPK signaling has been shown to lead to the development 
of all cancers (Saxena et al., 2008). Therefore, the drugs that 
target Ras-ERK MAPK signaling are potential drugs for treat-
ing cancer. 
Ras signaling and cancer stem cells 
The Ras-ERK MAPK signaling pathway governs many cel-
lular processes in most animals and is deregulated in approxi-
mately one-third of all human cancers. Because of its impor-
tance in cancer, the Ras-ERK MAPK signaling pathway has 
been an attractive target for anti-cancer therapy. For example, 
Moon et al examined the role of two genes, APC and K-Ras, 
working in tandem in initiating colorectal cancer progression 
(Moon et al., 2014). The group’s data showed that a gain-of-
function mutation of the oncogenic K-Ras, fixing it in the ac-
tive, GTP-bound conformation, accelerates the ERK pathway, 
which in turn activates the Wnt/β-catenin pathway, inducing 
cancer stem cell marker expression in colorectal cancer cells 
(Moon et al., 2014). Increased contribution to tumorigenesis 
and liver metastasis in K-Ras (gf) was observed in the pres-
ence of loss-of-function mutations in adenomatous polyposis 
coli (APC), a negative regulator of β-catenin concentration, 
another condition characteristic of initial and intermediate 
stage colorectal cancer (Moon et al., 2014). The study uti-
lized specimens from human colorectal cancer patients and 
APCMin/+/K-RasLA2 mice, which were studied for their ability 
to form spheroids in vitro and tumors in vivo, respectively. A 
mouse xenograft model was also utilized using wild-type K-
Ras and mutant K-Ras cells to observe cancer stem cell acti-
vation as a result of K-Ras mutation. Therefore, Ras activation 
can initiate the formation of cancer stem cells through Wnt/β-
catenin activation. 
C. elegans Ras signaling 
The Ras-ERK MAPK signaling pathways governs many 
cellular processes, including proliferation, differentiation, cell 
fate specification, homeostasis, and survival in all eukaryotes. 
The Ras-ERK MAPK signaling pathways in the C. elegans 
germline are well described by Sundaram (Sundaram, 2006). 
Notably, core signaling pathways and their components are 
strikingly conserved (Fig. 4B) (Sundaram, 2006; Whelan et al., 
2012). Briefly, two different RTKs, LET-23 (an EGFR homolog) 
and EGL-15 (a FGFR homolog) stimulate LET-60 (a Ras ho-
molog) and its downstream cascade, consisting of LIN-45 (a 
Raf homolog), MEK2 (an MEK homolog) and MPK-1 (an ERK 
homolog) (Fig. 4B). This C. elegans Ras-ERK MAPK signal-
ing controls multiple developmental events, including meiotic 
cycle progression, oocyte activation, sperm fate specification, 
spermatogenesis, physiological apoptosis, axon guidance, 
and vulva development (Lee et al., 2006; Sundaram, 2006; 
Lee et al., 2007b; Morgan et al., 2010) (Fig. 4B). In wild-type 
C. elegans hermaphrodite germline, activated MPK-1/ERK 
was not detected in the distal germline (e.g., germline stem 
cell region and pre-meiotic region) but became abundant in 
the proximal part of the pachytene region and in maturing oo-
cytes (Lee et al., 2007a; Lee et al., 2007b) (Fig. 4C). Activated 
MPK-1/ERK is subject to two redundant modes of downregu-
lation in the germline stem cell region: FBF-1/-2 (members of 
PUF RNA-binding protein family) proteins act post-transcrip-
tionally to repress mpk-1/ERK mRNA and LIP-1 acts post-
translationally to inhibit MPK-1/ERK activity (Fig. 4C) (Lee et 
al., 2007a). This regulation is also conserved in human embry-
onic stem cells (Lee et al., 2007a; Whelan et al., 2012). There-
fore, the dual negative regulation of MAPK/ERK by both PUF 
repression and MKP (MAPK phosphatase) inhibition may be a 
conserved mechanism that influences both stem cell mainte-
nance and possibly tumor progression (Whelan et al., 2012). 
In C. elegans germline, additional regulators have also been 
identified as inhibitors of C. elegans Ras-ERK MAPK signal-
ing: LARP-1 (La-related protein) and Insulin signaling inhibit 
Ras-ERK MAPK signaling during oogenesis (Nykamp et al., 
2008; Lopez et al., 2013). PUF-8 (a member of PUF protein 
family) represses let-60/Ras mRNA expression in the germline 
stem cell region (Vaid et al., 2013). The germline center ki-
nase (GCK1) also represses apoptosis by inhibiting Ras-ERK 
MAPK signaling (Schouest et al., 2009). Therefore, the Ras-
ERK MAPK signaling is regulated positively or negatively by 
several regulators, including kinases, phosphatases, or RNA 
regulators. 
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Fig. 4. Ras signaling pathways and a strategy for the phenotype-based drug identification using C. elegans mutants. (A) Conserved 
Ras-ERK MAPK signaling pathways. (B) C. elegans Ras-ERK MAPK signaling pathway. (C) Schematic of adult wild-type hermaphrodite 
germline. MPK-1/ERK is activated in the proximal pachytene and developing oocytes (see red). In the distal germline, FBF-1/-2 and LIP-1 
repress MPK-1/ERK activation at the post-transcriptional and translational levels (Lee et al., 2007a). (D) The germline phenotype of tem-
perature-sensitive mpk-1(ga111) loss-of-function mutant. At 20°C, most mpk-1(ga111) mutants are fertile, but they are sterile due to pachy-
tene arrest at 25°C. DAPI staining shows normal pachytene cells (left) and arrested pachytene cells (right). (E) The germline phenotype of 
puf-8; lip-1 homozygote mutant at 20°C (left) and 25°C (right). The puf-8; lip-1 mutants produce only sperm (Mog phenotype) at 20°C, but 
spermatocytes are dedifferentiated into mitotically dividing cells, resulting in germline tumors at 25°C. (F) Strategy for the phenotype-based 
identification of drugs that either inhibit or activate Ras-ERK MAPK signaling using C. elegans mutants. 
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Phenotype-based drug discovery for Ras signaling using 
mpk-1 or puf-8; lip-1 mutants
Loss of Ras-ERK MAPK signaling results in germline steril-
ity due to abnormal meiotic progression and gametogenesis 
(Lee et al., 2007b). Intriguingly, this sterility phenotype was 
rescued by the inhibition of negative Ras-ERK MAPK regula-
tors (e.g., LIP-1) (Hajnal and Berset, 2002; Lee et al., 2006). 
In contrast, aberrant activation of Ras-ERK MAPK by removal 
of PUF-8 and LIP-1 promotes sperm fate at 20oC (Morgan et 
al., 2010) and induces germline tumors at 25oC (Cha et al., 
2012). For example, a temperature sensitive, mpk-1(ga111) 
loss-of-function mutant is mostly fertile at 20oC, but it is sterile 
at 25°C due to pachytene arrest (Fig. 4D). This sterile phe-
notype is rescued by the depletion of MPK-1 inhibitors (e.g., 
LIP-1) (Hajnal and Berset, 2002; Lee et al., 2006). In addi-
tion, activated MPK-1/ERK in puf-8; lip-1 mutant promotes 
spermatogenesis without switching into oogenesis (Mascu-
linization of germline (Mog) phenotype) at 20°C and devel-
ops germline tumors via dedifferentiation of spermatocytes at 
25°C (Fig. 4E) (Morgan et al., 2010; Cha et al., 2012; Datla et 
al., 2014). Surprisingly, inhibition of Ras-ERK MAPK signal-
ing by either genetic mutation or drug treatment (e.g., U0126) 
sufficiently rescued puf-8; lip-1 sterility (Morgan et al., 2010; 
Cha et al., 2012; Datla et al., 2014). Therefore, mpk-1(lf) mu-
tants and puf-8; lip-1 mutants (Table 1) are useful animals for 
the identification of drugs that may target Ras-ERK MAPK 
signaling positively or negatively (Fig. 4F). The specificity can 
be confirmed using let-60(n1046) gain-of-function mutant or 
a transgenic worm expressing LET-23 chimeras in which the 
TK domain was replaced with the human mutant TK domain 
(L858R or T790M-L858R). Both animals with hyperactive Ras-
ERK MAPK signaling in somatic vulva precursor cells induce a 
multivulva (Muv) phenotype. Notably, these muv phenotypes 
were rescued by the treatment of Ras-ERK MAPK inhibitors, 
including AG1478 (an EGFR-TK inhibitor), U0126 (a MEK in-
hibitor), Gefitinib, Manumycin, and Gliotoxin (Hara and Han, 
1995; Bae et al., 2012). Therefore, mutants and transgenic 
animals are a model system that can be used in signaling or 
mutation-specific screens for new anti-cancer drugs. 
FERTILITY-BASED IN VIVO HIGH-THROUGHPUT DRUG 
SCREENING AND DRUG TARGET IDENTIFICATION 
For large-scale high-throughput drug screening, we have 
recently developed a fertility and image-based, label-free 
high-throughput workflow (Benson et al., 2014). This auto-
mated high-content assay enables effect sorting of C. el-
egans mutants into a 384-well plate using the COPASTM 
Worm Sorter and rapidly measuring either fertility or sterility 
by scoring the number of viable progeny in wells (Benson et 
al., 2014). For example, homozygote mutants for puf-8; lip-1 
Fig. 5. Fertility and image-based high-throughput screening and In vitro DARTS using human MEK2 (hMEK2). (A) Fertility and image-
based high-throughput drug screening. Slightly modified from (Benson et al., 2014). Fluorescence images can be taken on the Arrayscan 
Vti/SpotDetector can identify numerous progeny in wells treated with drugs and DMSO control. (B) Scheme of DARTS. (C) U0126 protects 
hMEK2 from pronase degradation. In vitro DARTS technique was optimized using a purified GST-tagged human MEK2 (hMEK2) protein 
with U0126, a well-known MEK2 inhibitor and DMSO. U0126 stabilizes hMEK2 from 0.001 mg pronase. 
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are sterile and must be maintained as heterozygotes using a 
GFP-tagged balancer chromosome for chromosome II (e.g., 
mIn[mIs14(Pmyo-2::GFP) dpy-10(e128), called mc6g). Homo-
zygotes for experiments are typically selected by picking GFP-
negative mutants using a fluorescence microscope. However, 
for large-scale animal handling, it would be advantageous to 
automatically identify homozygote mutants using a fluores-
cent marker. To this end, we generated a puf-8/mc6g; lip-1/
lip-1; [Pmyo-2::mCherry] transgenic mutant strain expressing a 
red-fluorescent protein, mCherry, in the head (Fig. 5A). The 
incorporation of the red-head marker, allows effective isolation 
of homozygote puf-8; lip-1 mutants [GFP(-) and mCherry(+)] 
using an automatic worm sorter, COPASTM BIOSORT. Further-
more, the mCherry head marker also simplifies detection of 
puf-8; lip-1 progeny that is difficult to identify using bright field 
optics (Fig. 5A). For fertility and image-based high-throughput 
drug screening, mutants of Wnt, Notch, or Ras signaling path-
ways can be incorporated with the red-head marker (mCher-
ry), which allows to measure automatically either fertility or 
sterility by scoring the number of viable progeny in wells using 
Arrayscan Vti/SpotDetector (Benson et al., 2014). Detail meth-
ods are described in Benson et al (Benson et al., 2014).
To date, several drugs that target core components of each 
oncogenic signaling pathways through target-specific in vitro 
screening. Nontheless, the drugs also alter normal signaling 
pathways. Moreover, current affinity-based target identification 
approaches require each drug of interest to be immobilized to 
a bead or another affinity- or fluorescent- or radioactive-“tag” 
so that the target protein can be “pulled down”. However, the 
coupling of compounds to beads and other molecules could 
lead to alteration or loss of compound bioactivity and bind-
ing. Furthermore, these techniques are time-consuming and 
require extensive biochemistry or medicinal chemistry exper-
tise (Lomenick et al., 2009; Lomenick et al., 2011). Recently, 
Huang and colleagues reported that the molecular target of 
the identified drug could be identified using a newly developed 
technique, called Drug Affinity Responsive Target Stability 
(DARTS) (Fig. 5B) (Lomenick et al., 2009; Lomenick et al., 
2011). DARTS takes advantage of the concept that protease 
susceptibility of the target protein is reduced upon drug bind-
ing (Lomenick et al., 2009; Lomenick et al., 2011). The ad-
vantage of this approach is that it is universally applicable as 
modification of the drug is not necessary and is independent 
of the mechanism of drug action. In particular, The DARTS is 
useful for the initial identification of the targets of compounds, 
but can also be useful for validation of potential protein-
ligand interaction (Lomenick et al., 2011). To test whether 
the DARTS is useful for molecular target identification of the 
identified drugs, we established an in vitro DARTS technique 
using a purified GST-tagged human MEK2 (hMEK2) protein 
with U0126, a well-known MEK2 inhibitor (Duncia et al., 1998; 
Favata et al., 1998) and DMSO (control) (Fig. 5C). Interest-
ingly, U0126 (1 uM) stabilized MEK2 protein, thereby reducing 
protease (pronase) sensitivity of the MEK2 protein (Fig. 5C). 
Although DARTS is a suitable and feasible method to identify 
the oncogenic target of the drugs, it remains still a major chal-
lenge if this method can be applied for all drug targets.
CONCLUSIONS
In this review, we describe three conserved oncogenic 
signaling pathways that are often associated with the de-
velopment of cancer stem cells. Importantly, these signaling 
pathways are highly conserved and critical for germline devel-
opment in C. elegans. Therefore, aberrant regulations of these 
signaling pathways cause either partially or completely sterile. 
Notably, inhibition or activation of these signaling pathways by 
drug treatment retains fertility (Morgan et al., 2010; Benson 
et al., 2014). Based on this finding, we here propose possible 
phenotype-based high-throughput screening methods to iden-
tify drugs that may alter oncogenic signaling pathways. The 
identification of drugs is a powerful tool of biological analy-
sis and therapeutics as well as can lead to the development 
of new drugs. However, a critical bottleneck is generating 
useful drug tools is target identification. Current target iden-
tification techniques have several limitations. For example, 
affinity-based target identification is limited by the necessary 
to modify each individual without losing bioactivity, and non-
affinity-based approaches depend on the drug’s ability to in-
duce specific biochemical or cellular readouts (Lomenick et 
al., 2009; Lomenick et al., 2011). Recently, Huang and col-
leagues established DARTS as a new technique (Lomenick 
et al., 2009; Lomenick et al., 2011). This technique is able to 
identify the targets of drugs based on the principle that when 
a drug binds to a protein, the interaction stabilizes the target 
protein’s structure, resulting in proteolytic resistance (Lo-
menick et al., 2009; Lomenick et al., 2011). If the specific tar-
gets of drugs are identified by DARTS technique, the peptides 
can be identified by mass-spectrometry after trypsin digestion. 
Therefore, these approaches, described in this review, have 
great potential for finding new drugs and will also aid research 
in cancer therapies. 
C. elegans has also emerged as an attractive model sys-
tem for functional analyses of bioactive compounds (e.g., 
nicotine) and natural components. Previously, Xu and col-
leagues developed a C. elegans model of nicotine-dependent 
behavior (Feng et al., 2006). They showed that C. elegans 
displays acute and chronic behavioral responses through 
nAChRs (nicotinic acetylcholine receptor, acr-5 and acr-15 in 
C. elegans) that are known to be critical for nicotine depen-
dence in mammals (Feng et al., 2006; Sellings et al., 2013). 
In addition, chronic nicotine exposure can alter the expression 
of microRNAs and genes that are implicated in reproduction, 
cholinergic signaling and stress responses (Smith et al., 2013; 
Taki et al., 2014). Kim and colleagues have also reported the 
effect of the isolated 1,2,3,4,6-penta-O-galloyl-b-D-glucose 
(PGG) from Curcuma longa L. on longevity using C. elegans 
as a model system (Ahn et al., 2013). Notably, they demon-
strated that PGG reduced intracellular ROS (Reactive Oxygen 
Species) accumulation through elevated SOD (Superoxide 
Dismutase). C. elegans has been used for the discoveries of 
antimicrobial drugs (Ewbank and Zugasti, 2011; Squiban and 
Kurz, 2011), antifungal drugs (Anastassopoulou et al., 2011), 
and Alzheimer’s disease drugs (Lublin and Link, 2013). There-
fore, C. elegans provides a tremendous promise for the dis-
covery of new disease or target-specific drugs, and studying 
the action mechanism of the newly identified or known drugs 
(or small-molecules) in a live animal. 
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